Prota Therapeutics Pty Ltd (Prota), an Australian biotechnology company focused on the development of novel oral immunotherapy treatments that induce remission of allergy, has on Tuesday announced financing of $21 million in equity and debt financing. The round is led by Singapore-based SPRIM Global Investments (SGI).